Topical phosphoinositide 3-kinase inhibitors

1. A compound having formula (I):

or a hydrate, solvate, and/or a pharmaceutically acceptable salt thereof,

wherein:

subscript m is an integer from 0 to 2; and

i) L 1 is —C(O)—, —C(O)O—, —C(O)S—, or —C(O)NH—; and

R 1 is C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, C 2-6 alkenyl, C 6-10 aryl, C 6-10 aryl-C 1-6 alkyl, or C 6-10 aryl-C 2-6 alkenyl;

ii) L 1 -R 1 has the formula:

wherein

the wavy line indicates the attachment to the adjacent oxygen atom in formula (I);

subscript t is an integer from 0 to 1;

subscripts p and q are independently an integer from 0 to 2;

R 3 is hydrogen or a sidechain of a natural or unnatural amino acid and R 4 is hydrogen, or R 3 and R 4 are combined to be a sidechain of a cyclic amino acid;

R 5 is hydrogen or a sidechain of a natural or unnatural amino acid and R 6 is hydrogen, C 1-6 alkyl, or C 2-6 alkenyl, or R 5 and R 6 are combined to be a sidechain of a cyclic amino acid; and

R 7 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 1-6 alkyl-C(O)—, or C 2-6 alkenyl-C(O)—, or

R 5 is hydrogen or a sidechain of a natural or unnatural amino acid; and

R 6 and R 7 are combined to form a 3-6 membered heterocycle, optionally having an additional 1-2 heteroatoms selected from O, S, and N as ring vertices; or

iii) L 1 is —C(O)—; and

R 1 is an aliphatic chain of a saturated fatty acid having 8-18 carbon atoms or an unsaturated fatty acid having 10-18 carbon atoms.

2. The compound of claim 1 , wherein subscript m is 0 or 1.

3. The compound of claim 1 , having formula (II) or (III):

4. The compound of claim 1 , having formula (IIa):

5. The compound of claim 4 , wherein R 1 is C 1-6 alkyl.

6. The compound of claim 4 , wherein R 1 is methyl or ethyl.

7. The compound of claim 1 , having the formula

8. The compound of claim 7 , wherein R 1 is C 1-6 alkyl.

9. The compound of claim 7 , wherein R 1 is methyl or ethyl.

10. The compound of claim 1 , wherein R 1 is methyl or ethyl.

11. The compound of claim 1 , wherein R 1 is phenyl-CH═CH—.

12. The compound of claim 1 , wherein subscripts p and q are each 0.

13. The compound of claim 12 , having formula (IIa-1) or (IIIa-1):

14. The compound of claim 1 , wherein the saturated fatty acid having 8-18 carbon atoms is selected from the group consisting of caprylic acid, pelargonic acid, capric acid, neodecanoic acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, and isostearic acid.

15. The compound of claim 1 , wherein the unsaturated fatty acid having 10-18 carbon atoms is selected from the group consisting of caproleic acid, lauroleic acid, myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, vaccenic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, columbinic acid, pinolenic acid, and stearidonic acid.

16. The compound of claim 1 , selected from the group consisting of:

17. The compound of claim 1 , represented by the formula:

or a pharmaceutically acceptable salt thereof.

18. The compound of claim 1 , represented by the formula:

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 , represented by the formula:

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1 , represented by the formula:

or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1 , represented by the formula:

or a pharmaceutically acceptable salt thereof.

22. The compound of claim 1 , represented by the formula:

or a pharmaceutically acceptable salt thereof.

23. The compound of claim 1 , represented by the formula:

or a pharmaceutically acceptable salt thereof.

24. The compound of claim 1 , represented by the formula:

or a pharmaceutically acceptable salt thereof.